Intravitreal injection

Definition

An intravitreal injection is a shot of medicine into the eye. The inside of the eye is filled with a jelly-like fluid (vitreous). During this procedure, your health care provider (usually an ophthalmologist) injects medicine into the vitreous, near the retina at the back of the eye. The medicine can treat certain eye problems and help protect your vision. This method is most often used to get a higher level of medicine to the retina.

Alternative Names

Antibiotic - intravitreal injection; Triamcinolone - intravitreal injection; Dexamethasone - intravitreal injection; Lucentis - intravitreal injection; Avastin - intravitreal injection; Bevacizumab - intravitreal injection; Ranibizumab - intravitreal injection; Anti-VEGF medicines - intravitreal injection; Macular edema - intravitreal injection; Retinopathy - intravitreal injection; Retinal vein occlusion - intravitreal injection

Description

The procedure is done in your provider's office. It takes about 15 to 30 minutes.

Why the Procedure Is Performed

You may have this procedure if you have:

Sometimes, an intravitreal injection of antibiotics and steroids is given as part of routine cataract surgery. This avoids having to use drops after surgery.

Risks

Side effects are rare, and many can be managed. They may include:

Discuss the risks for specific medicines used in your eye with your provider.

Before the Procedure

Tell your provider about:

After the Procedure

Following the procedure:

Report any eye pain or discomfort, redness, sensitivity to light, or changes in your vision to your provider right away.

Schedule a follow-up appointment with your provider as directed.

Outlook (Prognosis)

Your outlook depends mostly on the condition being treated. Your vision may remain stable or improve after the procedure. You may need more than one injection.

References

American Academy of Ophthalmology website. Age-related macular degeneration PPP 2019. www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp. Updated March 2022. Accessed February 6, 2023.

Kim JW, Berry JL, Murphree AL. Retinoblastoma. In: Sadda SVR, Sarraf D, Freund KB, et al, eds. Ryan's Retina. 7th ed. Philadelphia, PA: Elsevier; 2023:chap 129.

Rodger DC, Shildkrot YE, Eliott D. Infectious endophthalmitis. In: Yanoff M, Duker JS, eds. Ophthalmology. 6th ed. Philadelphia, PA: Elsevier; 2023:chap 7.8.

Shultz RW, Maloney MH, Bakri SJ. Intravitreal injections and medication implants. In: Yanoff M, Duker JS, eds. Ophthalmology. 6th ed. Philadelphia, PA: Elsevier; 2023:chap 6.11.



Review Date: 11/10/2022
Reviewed By: Franklin W. Lusby, MD, Ophthalmologist, Lusby Vision Institute, La Jolla, CA. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, timeliness, or correctness of any translations made by a third-party service of the information provided herein into any other language. © 1997- A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
© 1997- adam.comAll rights reserved.